Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer

Journal of Clinical Microbiology

Volumn 50, Issue 2, 2012, Pages 300-306

  Marks, Morgan A ^a   Castle, Philip E ^b   Schiffman, Mark ^c   Gravitt, Patti E ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b American Society for Clinical Pathology Institute   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 67; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN PAPILLOMAVIRUS TYPE 82; HUMAN PAPILLOMAVIRUS TYPE 82V; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOM SAMPLE; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

ADULT; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84856160240     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05979-11     Document Type: Article

References (25)

1. ASCUS-LSIL Triage Study (ALTS) Group. 2003. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 188:1383-1392.
2. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. 2008. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J. Clin. Microbiol. 46:109-117.
3. Castle PE, et al. 2009. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 339:b2569.
4. Castle PE, et al. 2008. Human papillomavirus genotype specificity of hybrid capture 2. J. Clin. Microbiol. 46:2595-2604.
5. Dillner J, et al. 2008. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 337:a1754.
6. Gage JC, Schiffman M, Solomon D, Wheeler CM, Castle PE. 2010. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. Cancer Epidemiol. Biomarkers Prev. 19:1668-1674.
7. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. 2008. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol. Biomarkers Prev. 17:1248-1254.
8. Gyllensten U, Lindell M, Gustafsson I, Wilander E. 2010. HPV test shows low sensitivity of Pap screen in older women. Lancet Oncol. 11:509-510. (Letter.)
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:423-428. (Pubitemid 28135669)
10. Ho GY, et al. 1995. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87:1365-1371.
11. Kjaer SK, et al. 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325:572.
12. Leisenring W, Pepe MS, Longton G. 1997. A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med. 16:1263-1281. (Pubitemid 27252596)
13. Marks M, et al. 2009. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time PCR. J. Virol. Methods 156:152-156.
14. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. 2006. HPV in the etiology of human cancer. Vaccine 24(Suppl. 3):S1-S10.
15. Ronco G, et al. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249-257.
16. Schiffman M, Adrianza ME. 2000. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol. 44:726-742.
17. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907. (Pubitemid 47371147)
18. Schiffman M, et al. 2005. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84. (Pubitemid 40725441)
19. Schiffman M, Solomon D. 2003. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch. Pathol. Lab. Med. 127:946-949. (Pubitemid 36994853)
20. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE. 2005. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am. J. Clin. Pathol. 124:722-732. (Pubitemid 41532507)
21. Schlecht NF, et al. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106-3114. (Pubitemid 34016525)
22. Sherman ME, et al. 2003. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer Inst. 95:46-52. (Pubitemid 36124295)
23. Walboomers JM, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19. (Pubitemid 29406813)
24. Winer RL, et al. 2005. Development and duration of human papillomavirus lesions, after initial infection. J. Infect. Dis. 191:731-738. (Pubitemid 40271061)
25. Wright TC, Jr., et al. 2007. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low Genit. Tract. Dis. 11:201-222.